Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 3150-3152

  Vaudaux, Pierre ^a   Fleury, Bénédicte ^a   Gjinovci, Asllan ^a   Huggler, Elzbieta ^a   Tangomo Bento, Manuela ^a   Lew, Daniel P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TIGECYCLINE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG TISSUE LEVEL; FOREIGN BODY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION;

ANIMALS; ANTI-BACTERIAL AGENTS; FOREIGN BODIES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MINOCYCLINE; RATS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 67649997359     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01612-08     Document Type: Article

References (40)

1. Bradford, P. A., P. J. Petersen, M. Young, C. H. Jones, M. Tischler, and J. O'Connell. 2005. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob. Agents Chemother. 49:3903-3909.
2. Cagni, A., C. Chuard, P. E. Vaudaux, J. Schrenzel, and D. P. Lew. 1995. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1655-1660.
3. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, and S. K. Fridkin. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.
4. Chopra, I. 2002. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist. Updates 5:119-125.
5. Chuard, C., M. Herrmann, P. Vaudaux, F. A. Waldvogel, and D. P. Lew. 1991. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob. Agents Chemother. 35:2611-2616.
6. Chuard, C., J. C. Lucet, P. Rohner, M. Herrmann, R. Auckenthaler, F. A. Waldvogel, and D. P. Lew. 1991. Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J. Infect. Dis. 163:1369-1373.
7. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Crandon, J. L., M. A. Banevicius, and D. P. Nicolau. 2009. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob. Agents Chemother. 53:1165-1169.
9. Draghi, D. C., S. Tench, M. J. Dowzicky, and D. F. Sahm. 2008. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy 54:91-100.
10. Fluit, A. C., A. Florijn, J. Verhoef, and D. Milatovic. 2005. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob. Agents Chemother. 49:1636-1638.
11. Garrison, M. W., J. J. Neumiller, and S. M. Setter. 2005. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms. Clin. Ther. 27:12-22.
12. Hiramatsu, K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155.
13. Hope, R., M. Warner, S. Mushtaq, M. E. Ward, T. Parsons, and D. M. Livermore. 2005. Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines. J. Antimicrob. Chemother. 56:1042-1046.
14. Labthavikul, P., P. J. Petersen, and P. A. Bradford. 2003. In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob. Agents Chemother. 47:3967-3969.
15. Liu, C., and H. F. Chambers. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47:3040-3045.
16. Lowy, F. D. 2003. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Investig. 111:1265-1273.
17. Lucet, J. C., M. Herrmann, P. Rohner, R. Auckenthaler, F. A. Waldvogel, and D. P. Lew. 1990. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 34:2312-2317.
18. McAleese, F., P. Petersen, A. Ruzin, P. M. Dunman, E. Murphy, S. J. Projan, and P. A. Bradford. 2005. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob. Agents Chemother. 49:1865-1871.
19. Muralidharan, G., M. Micalizzi, J. Speth, D. Raible, and S. Troy. 2005. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49:220-229.
20. Murillo, O., A. Domenech, G. Euba, R. Verdaguer, F. Tubau, J. Cabo, C. Cabellos, F. Gudiol, and J. Ariza. 2008. Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. J. Infect. 57:229-235.
21. Murphy, T. M., J. M. Deitz, P. J. Petersen, S. M. Mikels, and W. J. Weiss. 2000. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob. Agents Chemother. 44:3022-3027.
22. Noskin, G. A. 2005. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis. 41(Suppl. 5):S303-S314.
23. Olson, M. W., A. Ruzin, E. Feyfant, T. S. Rush III, J. O'Connell, and P. A. Bradford. 2006. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob. Agents Chemother. 50:2156-2166.
24. Ong, C. T., C. P. Babalola, C. H. Nightingale, and D. P. Nicolau. 2005. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J. Antimicrob. Chemother. 56:498-501.
25. Petersen, P. J., and P. A. Bradford. 2005. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob. Agents Chemother. 49:3910-3918.
26. Raad, I., H. Hanna, Y. Jiang, T. Dvorak, R. Reitzel, G. Chaiban, R. Sherertz, and R. Hachem. 2007. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother. 51:1656-1660.
27. Rose, W. E., and M. J. Rybak. 2006. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 26:1099-1110.
28. Rubinstein, E., and D. Vaughan. 2005. Tigecycline: a novel glycylcycline. Drugs 65:1317-1336.
29. Schaad, H. J., M. Bento, D. P. Lew, and P. Vaudaux. 2006. Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection. BMC Infect. Dis. 6:74.
30. Schaad, H. J., C. Chuard, P. Vaudaux, P. Rohner, F. A. Waldvogel, and D. P. Lew. 1994. Comparative efficacies of imipenem, oxacillin and vancomycin for therapy of chronic foreign body infection due to methicillin-susceptible and -resistant Staphylococcus aureus. J. Antimicrob. Chemother. 33:1191-1200.
31. Schaad, H. J., C. Chuard, P. Vaudaux, F. A. Waldvogel, and D. P. Lew. 1994. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 38:1703-1710.
32. Stein, G. E., and W. A. Craig. 2006. Tigecycline: a critical analysis. Clin. Infect. Dis. 43:518-524.
33. van Ogtrop, M. L., D. Andes, T. J. Stamstad, B. Conklin, W. J. Weiss, W. A. Craig, and O. Vesga. 2000. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 44:943-949.
34. Vaudaux, P. 1998. Phenotypic antibiotic tolerance of Staphylococcus aureus in implant-related infections: relationship with in vitro colonization of arti-ficial surfaces. Drug Resist. Updates 1:352-357.
35. Vaudaux, P., P. Francois, C. Bisognano, D. Li, D. P. Lew, and J. Schrenzel. 2003. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J. Antimicrob. Chemother. 52:89-95.
36. Vaudaux, P., P. Francois, C. Bisognano, J. Schrenzel, and D. P. Lew. 2002. Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46:1503-1509.
37. Vaudaux, P., A. Gjinovci, M. Bento, D. Li, J. Schrenzel, and D. P. Lew. 2005. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3789-3793.
38. Waldvogel, F. A., and A. L. Bisno. 2000. Infections associated with indwelling medical devices, p.1-436. American Society for Microbiology, Washington, DC.
39. Yin, L. Y., L. Lazzarini, F. Li, C. M. Stevens, and J. H. Calhoun. 2005. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J. Antimicrob. Chemother. 55:995-1002.
40. Zhanel, G. G., K. Homenuik, K. Nichol, A. Noreddin, L. Vercaigne, J. Embil, A. Gin, J. A. Karlowsky, and D. J. Hoban. 2004. The glycylcyclines: a comparative review with the tetracyclines. Drugs 64:63-88.